Publication Date:
2005-11-16
Description:
Purpose: Primary nasal NK/T-cell lymphoma is a highly aggressive tumor associated with poor response to therapy, frequent relapse, and a short median survival of 7–12 months. Moreover, the optimal treatment has not yet been established as most published studies were retrospective in nature. We performed a prospective study to evaluate the efficacy of combined m-BACOD chemotherapy and involved field radiotherapy (RT) for patients with previously untreated or relapsed nasal NK/T-cell lymphoma. Methods: Between January 1998 and December 2004, all previously untreated or relapsed patients (pts), aged 〉 18 years, with biopsy proven nasal NK/T-cell lymphoma, ECOG performance status 〈 2, and adequate marrow, cardiac, liver and renal functions were included in this study. Previously untreated pts were treated with m-BACOD (iv methotrexate 200mg/m2 D8, D15 with leucovorin rescue, iv bleomycin 4mg/m2 D1, iv doxorubicin 45mg/m2 D1, iv cyclophosphamide 600mg/m2 D1, and iv vincristine 1mg/m2, and dexamethasone 6mg/m2 D1-5 PO) every 3 weeks for 6 cycles, followed by involved field RT (54 Gy in 27 daily fractions over 5.4 weeks). Relapsed pts with prior anthacycline-based chemotherapy were treated with 3 cycles of m-BACOD, followed by RT. Stage I/II pts with static response (SR) after 3 cycles m-BACOD were treated with early RT. Young pts (
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink